(Q54409668)

English

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 (English)

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

1 reference

based on heuristic

inferred from title

14

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

object named as

Tamas Hickish

12

0 references

object named as

Janet Dunn

21

0 references

object named as

Helena M Earl

1

0 references

23

object named as

Carlos Caldas

1 reference

Europe PubMed Central

29 May 2018

7

object named as

Jean Abraham

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

author name string

Anne-Laure Vallier

2

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Louise Hiller

3

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Nicola Fenwick

4

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Jennie Young

5

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Mahesh Iddawela

6

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Luke Hughes-Davies

8

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Ioannis Gounaris

9

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Karen McAdam

10

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Stephen Houston

11

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Anthony Skene

13

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Susan Dean

15

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Diana Ritchie

16

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Robert Laing

17

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Mark Harries

18

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Christopher Gallagher

19

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Gordon Wishart

20

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Elena Provenzano

22

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Neo-tAnGo Investigators

24

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

publication date

19 December 2013

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Lancet Oncology Commission

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

15

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

2

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

201-212

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting of adjuvant breast cancer trials: when is the right time?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized p

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and accelerated drug approval in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970554-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70554-0

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

release_6ei6j427fbbadpsj4pc3hwyr3a

1 reference

https://api.fatcat.wiki/v0/release/6ei6j427fbbadpsj4pc3hwyr3a

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24360787

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54409668&oldid=1837066309"